Literature DB >> 11498350

Molecular mechanisms of resistance to taxanes and therapeutic implications.

Franco Zunino1, Giuliana Cassinelli, Donatella Polizzi, Paola Perego.   

Abstract

The mechanism of resistance to taxanes has not been fully elucidated. Since Taxol is a substrate for P-glycoprotein, overexpression of this transport system is recognized as a relevant mechanism of resistance. Additional mechanisms include changes of microtubule structure and/or composition resulting in reduced drug binding to the target. Current efforts are directed at clarifying the role of cellular response to drug-induced damage to cytoskeleton and mitotic spindle. Downstream events, such as control of cell cycle progression and regulation of cell death pathways, are likely to play a relevant role in cellular sensitivity to antimicrotubule agents. The identification of resistance factors and critical determinants of antitumor efficacy of microtubule-stabilizing agents is essential to (i) improve their therapeutic efficacy; and (ii) to design non-cross-resistant compounds. The present review discusses the possible therapeutic implications of the recent progress in the field of resistance to taxanes. Copyright 1999 Harcourt Publishers Ltd.

Entities:  

Year:  1999        PMID: 11498350     DOI: 10.1054/drup.1999.0108

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  8 in total

Review 1.  MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil.

Authors:  Fahima Danesh Pouya; Maria Gazouli; Yousef Rasmi; Dimitra Ioanna Lampropoulou; Mohadeseh Nemati
Journal:  Mol Biol Rep       Date:  2022-02-25       Impact factor: 2.742

Review 2.  MicroRNAs as therapeutic targets in chemoresistance.

Authors:  Michela Garofalo; Carlo M Croce
Journal:  Drug Resist Updat       Date:  2013-06-10       Impact factor: 18.500

3.  MicroRNA-mediated drug resistance in breast cancer.

Authors:  Kristy R Kutanzi; Olga V Yurchenko; Frederick A Beland; Vasyl' F Checkhun; Igor P Pogribny
Journal:  Clin Epigenetics       Date:  2011-06-27       Impact factor: 6.551

Review 4.  Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes.

Authors:  Maarten van Eijk; René J Boosman; Alfred H Schinkel; Alwin D R Huitema; Jos H Beijnen
Journal:  Cancer Chemother Pharmacol       Date:  2019-07-15       Impact factor: 3.333

5.  Nanoparticles design considerations to co-deliver nucleic acids and anti-cancer drugs for chemoresistance reversal.

Authors:  Sahar Eljack; Stephanie David; Areeg Faggad; Igor Chourpa; Emilie Allard-Vannier
Journal:  Int J Pharm X       Date:  2022-09-06

Review 6.  Cancer stem cells and strategies for targeted drug delivery.

Authors:  Jin Cao; Shubhmita Bhatnagar; Jiawei Wang; Xueyong Qi; Swayam Prabha; Jayanth Panyam
Journal:  Drug Deliv Transl Res       Date:  2020-10-23       Impact factor: 5.671

7.  Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft.

Authors:  G Petrangolini; G Cassinelli; G Pratesi; M Tortoreto; E Favini; R Supino; C Lanzi; S Belluco; F Zunino
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640

8.  Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer.

Authors:  Ching-Wen Chou; Yu-Min Huang; Yu-Jia Chang; Chien-Yu Huang; Chin-Sheng Hung
Journal:  Int J Med Sci       Date:  2021-04-26       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.